This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Szabó, D.
Right arrow Articles by Rozgonyi, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Szabó, D.
Right arrow Articles by Rozgonyi, F.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2001, p. 1287-1291, Vol. 45, No. 4
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.4.1287-1291.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

In Vitro and In Vivo Activities of Amikacin, Cefepime, Amikacin plus Cefepime, and Imipenem against an SHV-5 Extended-Spectrum beta -Lactamase-Producing Klebsiella pneumoniae Strain†

Dóra Szabó,1,* András Máthé,1 Zsolt Filetóth,2 Piroska Anderlik,1 László Rókusz,3 and Ferenc Rozgonyi1

Institute of Medical Microbiology, Semmelweis University,1 Clinical Epidemiology Unit of the National Institute of Traumatology,2 and Department of Infectology, Central Military Hospital,3 Budapest, Hungary

Received 7 April 2000/Returned for modification 16 November 2000/Accepted 17 January 2001

The in vitro and in vivo effectiveness of amikacin, cefepime, and imipenem was studied using a high inoculum of an extended-spectrum beta -lactamase-producing Klebsiella pneumoniae strain. An in vitro susceptibility test at the standard inoculum predicted the in vivo outcome of amikacin or imipenem while it did not do so for cefepime due to the inoculum effect.

* Corresponding author. Mailing address: Institute of Medical Microbiology, Semmelweis University Budapest, P.O. Box 370, H-1445 Budapest, Hungary. Phone and fax: 36-1210-29-59. E-mail: szabdor{at}net.sote.hu.

dagger This study was part of the 10th accredited Ph.D. program at Semmelweis University, Budapest, Hungary.

Antimicrobial Agents and Chemotherapy, April 2001, p. 1287-1291, Vol. 45, No. 4
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.4.1287-1291.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Livermore, D. M., Hawkey, P. M. (2005). CTX-M: changing the face of ESBLs in the UK. J Antimicrob Chemother 56: 451-454 [Abstract] [Full Text]  
  • Queenan, A. M., Foleno, B., Gownley, C., Wira, E., Bush, K. (2004). Effects of Inoculum and {beta}-Lactamase Activity in AmpC- and Extended-Spectrum {beta}-Lactamase (ESBL)-Producing Escherichia coli and Klebsiella pneumoniae Clinical Isolates Tested by Using NCCLS ESBL Methodology. J. Clin. Microbiol. 42: 269-275 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»